| BEFORE COMPLETING TREATMENT | AFTER COMPLETING TREATMENT |
|---|---|
| Be aware of the cardiotoxic potential of patients’ anti-cancer treatment plan Investigate new or changing cardiovascular symptoms | |
| Ensure patients are aware of the potential for heart problems during/after cancer treatment Monitor weight, lipid profile, glycaemic control during hormonal therapies Update the Oncologist early with relevant investigation results and medication changes |
Regular and relevant cardiac function testing no later than 6 months following high-risk treatments and if normal/asymptomatic Approach metastatic and non-metastatic patients with identical monitoring Liaise with a cardiologist if there is a suspicion of cardiotoxicity |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.